Maravai LifeSciences Holdings Inc. Class A Common Stock vs SoFi Technologies Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while SoFi Technologies Inc trades at $14.1 (market cap $19.68B). The key difference: SoFi Technologies Inc is far larger — about 20.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and SoFi Technologies Inc for 60 Days on average.
| MRVI | SOFI | |
|---|---|---|
Market Cap | $972.90M | $19.68B |
Volume | 4,325,710 | 30,790,556 |
Sector | Health | Financials |
52-Week High | $9.00 | $32.21 |
52-Week Low | $2.83 | $14.22 |
Typical Hold Time | 0 Days | 60 Days |
Enterprise Value | $1.08B | $19.83B |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SoFi Technologies stock trades at $14.22, down 6.63% with bearish technical signals. The company shows strong revenue growth from $2.6B in 2024 to $3.6B in 2025, with consistent earnings beats. However, negative operating cash flow and high P/E ratio of 31.1 present valuation concerns. Recent news highlights SoFi's stablecoin initiatives and record loan originations while the stock faces pressure from rising yields.
SoFi offers growth potential with expanding financial services but faces execution risks in a competitive fintech landscape. The stock trades at a discount to analyst consensus target of $21.08, though negative cash flow trends and market sensitivity to interest rates warrant caution. Investors should weigh strong fundamentals against technical weakness and macroeconomic headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →